Clinical Trial Update: Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing Foster pMDI (CHF 1535) with Symbicort Turbohaler in patients with chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Foster pMDI
• Symbicort Turbohaler (budesonide/formoterol)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED